262 related articles for article (PubMed ID: 24980176)
21. Treatment escalation in patients not responding to pharmacotherapy, psychotherapy, and electro-convulsive therapy: experiences from a novel regimen using intravenous S-ketamine as add-on therapy in treatment-resistant depression.
Kallmünzer B; Volbers B; Karthaus A; Tektas OY; Kornhuber J; Müller HH
J Neural Transm (Vienna); 2016 May; 123(5):549-52. PubMed ID: 26721476
[TBL] [Abstract][Full Text] [Related]
22. Evolving Issues in the Treatment of Depression.
Köhler-Forsberg O; Cusin C; Nierenberg AA
JAMA; 2019 Jun; 321(24):2401-2402. PubMed ID: 31125042
[No Abstract] [Full Text] [Related]
23. KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.
Bobo WV; Vande Voort JL; Croarkin PE; Leung JG; Tye SJ; Frye MA
Depress Anxiety; 2016 Aug; 33(8):698-710. PubMed ID: 27062450
[TBL] [Abstract][Full Text] [Related]
24. Role of copper and ketamine in major depressive disorder - an update.
Słupski J; Słupska A; Szałach ŁP; Włodarczyk A; Górska N; Szarmach J; Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wilkowska A; Wiglusz MS; Cubała WJ
Psychiatr Danub; 2019 Sep; 31(Suppl 3):520-523. PubMed ID: 31488784
[TBL] [Abstract][Full Text] [Related]
25. Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy.
Goforth HW; Holsinger T
J ECT; 2007 Mar; 23(1):23-5. PubMed ID: 17435569
[TBL] [Abstract][Full Text] [Related]
26. Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression.
Yang JJ; Wang N; Yang C; Shi JY; Yu HY; Hashimoto K
Biol Psychiatry; 2015 Feb; 77(3):e19-e20. PubMed ID: 25104172
[No Abstract] [Full Text] [Related]
27. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
DeWilde KE; Levitch CF; Murrough JW; Mathew SJ; Iosifescu DV
Ann N Y Acad Sci; 2015 May; 1345(1):47-58. PubMed ID: 25649308
[TBL] [Abstract][Full Text] [Related]
28. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.
Owen RT
Drugs Today (Barc); 2012 Jul; 48(7):469-78. PubMed ID: 22844658
[TBL] [Abstract][Full Text] [Related]
29. Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants.
Rotroff DM; Corum DG; Motsinger-Reif A; Fiehn O; Bottrel N; Drevets WC; Singh J; Salvadore G; Kaddurah-Daouk R
Transl Psychiatry; 2016 Sep; 6(9):e894. PubMed ID: 27648916
[TBL] [Abstract][Full Text] [Related]
30. [Ketamine for treatment of depression?].
Vinberg M
Ugeskr Laeger; 2013 Sep; 175(37):2089. PubMed ID: 24011202
[No Abstract] [Full Text] [Related]
31. Intravenous ketamine for treatment-resistant major depressive disorder.
Covvey JR; Crawford AN; Lowe DK
Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
[TBL] [Abstract][Full Text] [Related]
32. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases.
Paul R; Schaaff N; Padberg F; Möller HJ; Frodl T
World J Biol Psychiatry; 2009; 10(3):241-4. PubMed ID: 19224412
[TBL] [Abstract][Full Text] [Related]
33. Ketamine-induced affective switch in a patient with treatment-resistant depression.
Banwari G; Desai P; Patidar P
Indian J Pharmacol; 2015; 47(4):454-5. PubMed ID: 26288483
[TBL] [Abstract][Full Text] [Related]
34. Is Intravenous Ketamine Better Than Intranasal Esketamine for Treating Treatment-Resistant Depression?
Mansuri Z; Shah B; Yadav G; Kamil SH; Kainth T; Srinivas S; Patel H; Reddy A; Bachu A
Prim Care Companion CNS Disord; 2024 Feb; 26(1):. PubMed ID: 38382071
[No Abstract] [Full Text] [Related]
35. Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression.
Kantrowitz JT; Halberstam B; Gangwisch J
J Clin Psychiatry; 2015 Jun; 76(6):737-8. PubMed ID: 26132675
[No Abstract] [Full Text] [Related]
36. Riluzole likely lacks antidepressant efficacy in ketamine non-responders.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
J Psychiatr Res; 2014 Nov; 58():197-9. PubMed ID: 25139008
[No Abstract] [Full Text] [Related]
37. Oral racemic ketamine for common clinical contexts in patients with major depressive disorder: An important intervention that treatment guidelines may never include.
Andrade C
Bipolar Disord; 2022 Mar; 24(2):113-114. PubMed ID: 34816542
[No Abstract] [Full Text] [Related]
38. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB;
Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481
[TBL] [Abstract][Full Text] [Related]
39. Treatment Resistant Depression with Loss of Antidepressant Response: Rapid-Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule.
Lauterbach EC
Psychopharmacol Bull; 2016 Aug; 46(2):53-58. PubMed ID: 27738380
[TBL] [Abstract][Full Text] [Related]
40. [Ketamine in acute and severe major depressive disorder].
Brittner M; Micoulaud-Franchi JA; Richieri R; Boyer L; Adida M; Lancon C; Fond G
Presse Med; 2014 May; 43(5):492-500. PubMed ID: 24630265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
